Shots:
- Personalis has reported interim VICTORI study data assessing its NeXT Personal assay for the detection of early residual or recurrent CRC via ctDNA using blood samples from 71 pts with resectable Stage I-IV CRC
- At 15.75mos. mFU, 100% pts with recurrences, incl. distant metastases, were detected via ctDNA before imaging, with 87% detected within 2–8wks. & 85% by 4wks. post-surgery
- Within the landmark window, 64% of detections were in the ultrasensitive range (<100 PPM) while 70% of first ctDNA detections had a median of 24.4 PPM & as low as 2.45 PPM; 100% ctDNA-negative pts remained disease-free during the study. Data was presented at AACR 2025
Ref: BusinessWire | Image: Personalis
Related News:- Kardium Reports Preliminary PULSAR IDE Trial Data of Globe PF System for Paroxysmal Atrial Fibrillation (PAF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
